SCHEMBL2416865

SCHEMBL2416865

O=C(O)CCC(O)C(O)CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 3/20 0.50
KDM4A O75164 2/20 0.50
KDM4C Q9H3R0 2/20 0.50
KDM2A Q9Y2K7 2/20 0.50
TET3 O43151 1/20 0.50
FOLH1 Q04609 3/20 0.42
CYP1A2 P05177 2/20 0.42
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42
GABRA6 Q16445 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25492943 1.00 TET2 (0.50) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL10599631 0.89 TET2 (0.60) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL1244924 0.85 CAMK2A (0.46) TET2KDM4AKDM4CKDM2ALMNA
SCHEMBL12355088 0.85 CAMK2A (0.46) TET2KDM4AKDM4CKDM2ALMNA
SCHEMBL3687001 0.85 PDE4A (0.54) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL16600592 0.85 PDE4A (0.48) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL16600326 0.84 TET2 (0.50) TET2KDM4AKDM4CKDM2ATET3
SCHEMBL2473072 0.83 LMNA (0.50) LMNAENPEPNFKB1
SCHEMBL15153687 0.83 LMNA (0.50) LMNAENPEPNFKB1
SCHEMBL28908459 0.83 PDE4A (0.52) TET2KDM4AKDM4CKDM2ATET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223392-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC (CH) 2025-07-10 US disclosed
US-12286501-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof ALCON INC. (CH) 2025-04-29 US disclosed
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2025-04-24 US disclosed
US-20250059330-A1 SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2025-02-20 US disclosed
EP-4481478-A2 SILICONE HYDROGEL CONTACT LENSES Alcon Inc. (CH) 2024-12-25 EP disclosed
US-12162987-B2 Silicone hydrogel contact lenses ALCON INC. (CH) 2024-12-10 US disclosed
EP-4235274-B1 SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2024-10-09 EP disclosed
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo ENGENE, INC. (CA) 2024-09-03 US disclosed
US-20240254269-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC. (CH) 2024-08-01 US disclosed
US-11926689-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof ALCON INC. (CH) 2024-03-12 US disclosed
EP-3390498-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF Novartis AG (CH) 2018-10-24 EP disclosed
US-10081697-B2 Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof NOVARTIS AG (CH) 2018-09-25 US disclosed
EP-3231789-A1 BIOMARKERS FOR DIAGNOSING MULTIPLE SCLEROSIS, AND METHODS THEREOF Phenomenome Discoveries Inc. (CA) 2017-10-18 EP disclosed
WO-2017103790-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF NOVARTIS AG (CH) 2017-06-22 WO disclosed
US-20170166673-A1 HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF ALCON INC. (CH) 2017-06-15 US disclosed
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2016-08-18 US disclosed
US-20140024132-A1 METHODS AND SYSTEMS USING INTEGRATED METABOLOMICS AND PHARMACOKINETICS FOR MULTI-COMPONENT DRUG EVALUATION THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO 2014-01-23 US disclosed
EP-2396009-A1 COMPOSITIONS FOR THE TREATMENT OF APHTHOUS STOMATITIS Bonucci, Monica (IT) 2011-12-21 EP disclosed
WO-2011113066-A1 METHODS AND SYSTEMS USING INTEGRATED METABOLOMICS AND PHARMACOKINETICS FOR MULTI-COMPONENT DRUG EVALUATION THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) 2011-09-15 WO disclosed
WO-2010092534-A1 COMPOSITIONS FOR THE TREATMENT OF APHTHOUS STOMATITIS BONUCCI MONICA (IT) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885
US-20160235863-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP TET2 420/4885KDM4A 1237/4885KDM4C 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.